These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

622 related items for PubMed ID: 15389801

  • 21. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 22. Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells.
    Guo F, Sigua C, Tao J, Bali P, George P, Li Y, Wittmann S, Moscinski L, Atadja P, Bhalla K.
    Cancer Res; 2004 Apr 01; 64(7):2580-9. PubMed ID: 15059915
    [Abstract] [Full Text] [Related]

  • 23. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T.
    Cancer Res; 2005 Jul 15; 65(14):6364-70. PubMed ID: 16024639
    [Abstract] [Full Text] [Related]

  • 24. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
    Kang J, Bu J, Hao Y, Chen F.
    Prostate Cancer Prostatic Dis; 2005 Jul 15; 8(3):274-9. PubMed ID: 15897917
    [Abstract] [Full Text] [Related]

  • 25. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
    Shankar S, Singh TR, Fandy TE, Luetrakul T, Ross DD, Srivastava RK.
    Int J Mol Med; 2005 Dec 15; 16(6):1125-38. PubMed ID: 16273296
    [Abstract] [Full Text] [Related]

  • 26. Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inhibitory protein.
    Frese S, Brunner T, Gugger M, Uduehi A, Schmid RA.
    J Thorac Cardiovasc Surg; 2002 Jan 15; 123(1):168-74. PubMed ID: 11782771
    [Abstract] [Full Text] [Related]

  • 27. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K, Douglas L, Delaney A, Houghton JA.
    Clin Cancer Res; 2004 Oct 01; 10(19):6650-60. PubMed ID: 15475455
    [Abstract] [Full Text] [Related]

  • 28. Apo2L/TRAIL differentially modulates the apoptotic effects of sulindac and a COX-2 selective non-steroidal anti-inflammatory agent in Bax-deficient cells.
    He Q, Luo X, Huang Y, Sheikh MS.
    Oncogene; 2002 Sep 05; 21(39):6032-40. PubMed ID: 12203115
    [Abstract] [Full Text] [Related]

  • 29. Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.
    LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A.
    Nat Med; 2002 Mar 05; 8(3):274-81. PubMed ID: 11875499
    [Abstract] [Full Text] [Related]

  • 30. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M, Ettenberg SA, Nau MM, Lipkowitz S.
    Gynecol Oncol; 2001 Jun 05; 81(3):380-90. PubMed ID: 11371126
    [Abstract] [Full Text] [Related]

  • 31. Sulforaphane enhances the therapeutic potential of TRAIL in prostate cancer orthotopic model through regulation of apoptosis, metastasis, and angiogenesis.
    Shankar S, Ganapathy S, Srivastava RK.
    Clin Cancer Res; 2008 Nov 01; 14(21):6855-66. PubMed ID: 18980980
    [Abstract] [Full Text] [Related]

  • 32. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR.
    Biochem Pharmacol; 2006 Jul 28; 72(3):293-307. PubMed ID: 16753135
    [Abstract] [Full Text] [Related]

  • 33. Low extracellular pH augments TRAIL-induced apoptotic death through the mitochondria-mediated caspase signal transduction pathway.
    Lee YJ, Song JJ, Kim JH, Kim HR, Song YK.
    Exp Cell Res; 2004 Feb 01; 293(1):129-43. PubMed ID: 14729063
    [Abstract] [Full Text] [Related]

  • 34. The essential role of the mitochondria-dependent death-signaling cascade in chemotherapy-induced potentiation of Apo2L/TRAIL cytotoxicity in cultured thoracic cancer cells: amplified caspase 8 is indispensable for combination-mediated massive cell death.
    Nguyen DM, Yeow WS, Ziauddin MF, Baras A, Tsai W, Reddy RM, Chua A, Cole GW, Schrump DS.
    Cancer J; 2006 Feb 01; 12(4):257-73. PubMed ID: 16925970
    [Abstract] [Full Text] [Related]

  • 35. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
    Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, Bryant JL, Srivastava RK.
    Cancer Res; 2003 Apr 01; 63(7):1712-21. PubMed ID: 12670926
    [Abstract] [Full Text] [Related]

  • 36. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
    Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ.
    Cancer Res; 2004 May 15; 64(10):3517-24. PubMed ID: 15150106
    [Abstract] [Full Text] [Related]

  • 37. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N, Poulaki V, Mitsiades C, Tsokos M.
    Cancer Res; 2001 Mar 15; 61(6):2704-12. PubMed ID: 11289151
    [Abstract] [Full Text] [Related]

  • 38. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK, VanOosten RL, Griffith TS.
    Cancer Res; 2006 Jan 01; 66(1):499-507. PubMed ID: 16397266
    [Abstract] [Full Text] [Related]

  • 39. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
    Wang S, El-Deiry WS.
    Proc Natl Acad Sci U S A; 2003 Dec 09; 100(25):15095-100. PubMed ID: 14645705
    [Abstract] [Full Text] [Related]

  • 40. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR, Ng CP, Gan XH, Schiller G, Bonavida B.
    Clin Cancer Res; 2001 Dec 09; 7(12):3874-83. PubMed ID: 11751478
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.